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Abstract
The Epstein-Barr virus (EBV)-encoded nuclear antigen EBNA1 is critical for the persistence of
the viral episome in replicating EBV-transformed human B cells. Therefore, all EBV-induced
tumors express this foreign antigen. However, EBNA1 is invisible to CD8⫹ cytotoxic T lymphocytes because its Gly/Ala repeat domain prevents proteasome-dependent processing for
presentation on major histocompatibility complex (MHC) class I. We now describe that CD4⫹
T cells from healthy adults are primed to EBNA1. In fact, among latent EBV antigens that
stimulate CD4⫹ T cells, EBNA1 is preferentially recognized. We present evidence that the
CD4⫹ response may provide a protective role, including interferon ␥ secretion and direct cytolysis after encounter of transformed B lymphocyte cell lines (B-LCLs). Dendritic cells (DCs)
process EBNA1 from purified protein and from MHC class II–mismatched, EBNA1-expressing cells including B-LCLs. In contrast, B-LCLs and Burkitt’s lymphoma lines likely present
EBNA1 after endogenous processing, as their capacity to cross-present from exogenous sources
is weak or undetectable. By limiting dilution, there is a tight correlation between the capacity
of CD4⫹ T cell lines to recognize autologous B-LCL–expressing EBNA1 and DCs that have
captured EBNA1. Therefore, CD4⫹ T cells can respond to the EBNA1 protein that is crucial
for EBV persistence. We suggest that this immune response is initiated in vivo by DCs that
present EBV-infected B cells, and that EBNA1-specific CD4⫹ T cell immunity be enhanced to
prevent and treat EBV-associated malignancies.
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Introduction
EBV is a human gamma herpesvirus with a tropism for B
lymphocytes (1). More than 95% of the adult population
carries EBV as a lifelong asymptomatic infection. Nevertheless, EBV has strong growth-transforming capacities (2).
Each of its three latency programs gives rise to specific tumors originating from B cells or other cell types. As exemplified by EBV-transformed B cells (B lymphocyte cell lines
[B-LCLs])1 or lymphoproliferative disease, the latency III

phenotype is characterized by the expression of nine gene
products: six EBV nuclear antigens (EBNA1, EBNA2,
EBNA3A, EBNA3B, EBNA3C, and EBNALP) and three
latent membrane proteins (LMP1, LMP2A, and LMP2B)
(3). In latency II, EBV-associated malignancies like
Hodgkin’s lymphoma, nasopharyngeal carcinoma, T cell
lymphoma, gastric carcinoma, and uterine leiomyosarcoma,
three specific EBV genes, EBNA1, LMP1, and LMP2, are
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to search for CD4⫹ T cell responses to individual latent
EBV products. For EBNA1, we delivered the antigen as
recombinant protein (42–45), in recombinant vaccinia virus (vv) constructs, and by coculturing with B-LCLs. We
have uncovered a strong CD4⫹ T cell response to EBNA1,
as monitored by T cell activation and proliferation, IFN-␥
secretion, and CTL activity. Paralleling the above results
with one EBNA2-specific CD4⫹ T cell clone, we demonstrate that the EBNA1-specific CD4 responses—generated
routinely from adult blood samples—recognize HLA-DR–
matched B-LCLs and therefore could provide resistance to
EBV infection and EBV-associated malignancy.

Materials and Methods
Cell Lines. The EBV-transformed B cell lines LRM (HLAA2, -B44, -DRB1*0401, -DQA1*03, -DQB1*0301, and -DP4)
(46), LG2 (HLA-DRB1*0101, -DQA*0101, -DQB1*0501,
-DPA1*0101, and -DPB1*0201) (47), and newly generated
B-LCL and the Burkitt’s lymphoma lines Ramos, EBV⫺, and
Daudi, reverted to latency III (obtained from American Type
Culture Collection), were cultured in RPMI 1640/10% FCS/
glutamine/gentamicin. LCL-JT (HLA-DRB1*0301 and -DRB1*
1301), LCL-BM (HLA-A1, -A3, -B7, -B8, -Cw6, -Cw7, -DR4,
-DRw14, -DRw52, -DRw53, and -DQw3), LCL-DC (HLA-A2,
-A24, -B38, -B46, -Cw1, -Cw7, -DRB1*1502, -DRB1*0901,
-DRB4*01, -DRB5*0101, -DQB1*0502, and -DQB1*0303),
LCL-BC (HLA-DRB1*0401, -DRB1*0701, DRB4*01, -DQB1*
0302, and -DQB1*0201), and buffy coat–derived B-LCLs were
generated by culturing PBMCs of healthy donors with supernatant of the marmoset cell line B95.8 in RPMI 1640/20% FCS/
glutamine/gentamicin/1 g/ml cyclosporin A. The rabbit RK13
and monkey BSC40 kidney cell line was grown in DMEM/15%
FCS/glutamine/gentamicin.
DC and PBMC Preparations. Leukocyte concentrates (buffy
coats) from the New York Blood Center, as well as whole blood
from lab donors, served as sources of PBMCs isolated by density
gradient centrifugation on Ficoll-Paque (Amersham Pharmacia
Biotech). CD2⫹ PBMCs were separated by rosetting with
neuraminidase-treated (Calbiochem) sheep RBCs (Colorado Serum Company) followed by red cell lysis with 1.66% ammonium
chloride. Where indicated, CD8⫹ or CD4⫹ T cells were depleted
with Leu2a or OKT8 (for CD8) or HP2/6 (for CD4) antibodies,
followed by incubation with sheep anti–mouse IgG Dynabeads
and a magnetic particle concentrator, MCP-1 (Dynal). Positive
selection for CD4⫹ PBMCs was performed using anti-CD4 MicroBeads, MS⫹/RS⫹ columns, and MiniMACS separator (Miltenyi Biotec). DCs were generated from CD2⫺ PBMCs as described (48). 106 CD2⫺ PBMCs/ml were plated in 6-well plates
with RPMI 1640/1% single donor plasma/glutamine/gentamicin. 100 l medium was replaced at days 2, 4, and 6. Recombinant human (rh)IL-4 and rhGM-CSF were added to a final concentration of 1,000 U/ml at days 0, 2, 4, and 6. On day 7, the
floating immature DCs were transferred to new plates at 3 ⫻ 105
cells/ml and half of the medium was replaced by monocyte-conditioned medium to mature the DCs for 2 d. DCs and T cells
were used fresh or after cryopreservation.
Vaccinia Virus Stock Generation and Infection of DCs. Recombinant vv were expanded in rabbit RK13 and titrated on monkey
BSC40 kidney cells. Mature DCs were infected at a multiplicity
of infection (MOI) of 2 for 1 h at 37⬚C and washed three times.
The efficiency of infection was checked after 6–12 h by FACS®
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maintained (3). Burkitt’s lymphoma exemplifies the EBV
latency I phenotype. Only the EBNA1 protein is expressed
in these transformed B cells.
EBNA1, LMP1, and LMP2 are probably critical for tumorigenesis, inducing cell proliferation as well as resistance
to apoptosis (4). EBNA1 binds as a dimer to the viral origin
of replication and ensures episomal replication during B
cell growth (5–8). The COOH-terminal part of LMP1 can
act as a direct oncogene (9–11) by mimicking CD40-mediated B cell activation (12–15). Thus, LMP1 engages signaling proteins for the TNF receptor family (16, 17) and Janus
kinase 3 (18), ultimately leading to nuclear factor B (17)
and AP-1 (Jun/Jun or Jun/Fos) (19) induction. In addition,
LMP1 expression protects against apoptosis by induction of
bcl-2 (20, 21). Instead, LMP2 mimics B cell receptor signaling, constitutively engaging syk and lyn, protein tyrosine
kinases (22). In Burkitt’s lymphoma, only EBNA1 seems to
be required, as transformation is achieved by additional
mechanisms probably involving c-myc uncoupling through
chromosomal translocation (2). However, the increased incidence of B cell neoplasia in EBNA1 transgenic mice argues for an involvement of this EBV product in transformation even in latency I malignancies (23).
How then is transformation to latency I and II malignancies avoided in most carriers of EBV? Immunity to EBNA1
a priori could provide resistance to transformed cells, but it
has proven difficult to detect specific T cell responses to
this essential protein for EBV persistence. In fact, EBNA1
blocks its own processing for MHC class I presentation
(24). This has been attributed to a deficit in proteasomal
processing, caused by the NH2-terminal Gly/Ala (GA) repeat domain (25, 26). A similar GA stretch prevents IB␣
degradation by the proteasome (27). Other EBV latency
gene products are the focus of a strong MHC class I–restricted
CTL response, especially EBNA3A, EBNA3B, and EBNA3C
(28). However, EBNA3 proteins are not expressed in most
of the EBV-associated tumors mentioned above, and instead are expressed in transformed cultured lines (B-LCLs)
and lymphoproliferative syndromes in immunosuppressed
patients. CD8⫹ CTL responses to tumor-associated LMP1
(29) and LMP2 (30) proteins have only occasionally been
detected.
It has been repeatedly apparent that the development
(31–33) and maintenance (34–37) of effective CD8⫹ CTLs
are dependent on CD4⫹ T cell help. Recognition of EBV
products by CD4⫹ T cells has not been investigated in the
same detail as the CD8⫹ T cell response (38). Only two
EBV-specific CD4⫹ T cell clones have been described
before (39, 54). While the EBNA2-specific CD4⫹ T cell
clone recognized HLA-DQ–matched B-LCLs, the
EBNA1-specific CD4⫹ T cell clone only killed targets after
exogenous loading with recombinant EBNA1 protein.
Therefore, it was suggested that EBNA1 prevents its own
endogenous presentation onto MHC class II, and that
CD4⫹ T cell recognition of EBNA1 does not mediate protective immunity against EBV-associated malignancies.
Dendritic cells (DCs) are potent APCs for CD4⫹ and
CD8⫹ T cell immunity (40, 41). Therefore, we used DCs

Table I. Percentages of Blasting CD4⫹ T Lymphocytes upon Stimulation with DCs Infected with Recombinant Vaccinia-EBV Viruses
Donor no.

vvEBNA1

vvEBNA3A

vvEBNA3B

vvEBNA3C

vvLMP1

vvLMP2A

vvBMLF1

Influenza

4*
2
0
1
1
2
3
1
2
5

17 (2‡)
15 (3)
11 (6)
11 (6)
15 (4)
8 (3)
11 (6)
12 (4)
8 (0)
18 (3)

22 (8)
6 (2)
0 (0)
1 (1)
1 (1)
ND
2 (2)
0 (0)
1 (0)
5 (3)

11 (3)
17 (8)
19 (8)
12 (7)
4 (2)
2 (2)
2 (2)
10 (2)
3 (0)
3 (1)

ND
8 (3)
0 (0)
2 (1)
3 (1)
1 (2)
1 (1)
2 (1)
4 (2)
17 (3)

23 (3)
8 (2)
30 (18)
14 (10)
6 (1)
5 (1)
3 (2)
8 (9)
18 (5)
8 (2)

8 (4)
3 (2)
0 (0)
1 (0)
1 (1)
3 (3)
3 (1)
2 (2)
5 (0)
4 (1)

3 (3)
0 (0)
0 (0)
1 (0)
0 (1)
ND
3 (3)
9 (8)
4 (4)
5 (2)

17 (6)
12 (3)
28 (10)
35 (6)
13 (10)
15 (7)
34 (11)
7 (3)
2 (1)
25 (3)

*Incubations were performed with vv-infected autologous mature DCs and monitored by flow cytometry after two stimulations.
‡Values in parentheses reflect blasted subpopulations that were restimulated with vvTK ⫺-infected DCs as control.

as described using intracellular staining of a vaccinia early protein
of 29 kD with the VV1-6B6 antibody (49).
Generation of CD4⫹ T Cell Lines and Clones. CD8⫺CD2⫹ or
CD4⫹ PBMCs were stimulated with mature DCs at a ratio of 30:1
(T/DC). For the CM171198 cell line, T cells of the healthy donor CM (HLA-A*0201, -A*6801, -B*4402, -B*0702, -C*0501,
-C*0702, -DRB1*1501, -DRB1*0401, -DRB5*01, -DRB4*01,
-DQB1*0602, and -DQB1*0301) were stimulated for 4 wk with
vvEBNA1⌬GA-infected autologous mature DCs with weekly
restimulations including autologous CD2⫹ PBMCs as feeders,
and then alternating with the EBV-transformed HLA-DR–matched
cell line LRM or vvEBNA1⌬GA-infected DCs. The CM110199
cell line was generated from T cells of the donor CM by using
DCs that had been incubated with 10 M of recombinant
EBNA1 protein, added at day 7 together with the maturation
stimulus. Purified rEBNA1 from Escherichia coli and baculovirus/

insect cell expression systems were alternatively used (42, 45).
Where indicated, E. coli–derived DNA-C or PCNA were used as
control proteins (eControl). After 7–14 d of stimulation in
DMEM plus 5% human serum (HS), 50 U/ml rIL-2 was supplemented. The EBNA1-specific T cell line 090199.6 from leucocyte concentrates was established similarly from CD4⫹ PBMCs.
For stimulations with the autologous B-LCLs, CD2⫹ PBMCs of
the healthy donor JT were stimulated for 14 d with the irradiated
autologous LCL-JT at a B cell to T cell ratio of 1:10 in DMEM
plus 5% HS plus 10 U/ml IL-2 (Lymphocult). Where indicated,
CD4⫹ or CD8⫹ T cells were depleted. EBNA1-specific CD4⫹
CTLs were cloned under limiting dilution conditions by stimulating 105, 3 ⫻ 104 and 104 CD8⫺CD2⫹ PBMCs from leukocyte
concentrates or 30, 10, and 3 CM110199 cells with 104, autologous or HLA-DR–matched B-LCLs in 96-well plates for 14 d with
one restimulation at day 7. IL-2 was added to the cultures during

Table II. Number of IFN-␥–producing CD4⫹ T Lymphocytes upon Stimulation with DCs Infected with Recombinant Vaccinia-EBV Viruses
Donor no.

vvTK⫺

vvEBNA1

vvEBNA3A

vvEBNA3B

vvEBNA3C

vvLMP1

vvLMP2A

vvBMLF1

Influenza

5

7 ⫾ 1*

6

3⫾1

5⫾4
(7 ⫾ 4)
ND

1⫾1

8

3⫾1

9

2⫾1

10

5⫾1

2⫾1
(5 ⫾ 1)
5⫾1
(4 ⫾ 2)
2⫾1
(3 ⫾ 0)
25 ⫾ 4
(1 ⫾ 1)
5⫾2
(2 ⫾ 2)
13 ⫾ 3
(4 ⫾ 3)

6⫾2
(5 ⫾ 1)
3⫾1
(2 ⫾ 2)
2⫾0
(3 ⫾ 0)
1⫾1
(2 ⫾ 2)
8⫾4
(2 ⫾ 1)
108 ⫾ 3
(9 ⫾ 5)

4⫾1
(2 ⫾ 1)
4⫾2
(3 ⫾ 1)
2⫾2
(2 ⫾ 1)
64 ⫾ 2
(5 ⫾ 2)
25 ⫾ 5
(1 ⫾ 1)
38 ⫾ 1
(10 ⫾ 3)

10 ⫾ 4
(6 ⫾ 1)
6⫾3
(2 ⫾ 2)
6⫾4
(1 ⫾ 0)
6⫾2
(2 ⫾ 1)
10 ⫾ 3
(3 ⫾ 1)
14 ⫾ 1
(7 ⫾ 2)

1⫾1
(2 ⫾ 1)
ND

7

23 ⫾ 1
(7 ⫾ 4‡)
88 ⫾ 8
(37 ⫾ 1)
16 ⫾ 1
(4 ⫾ 1)
36 ⫾ 1
(6 ⫾ 2)
17 ⫾ 1
(1 ⫾ 1)
48 ⫾ 3
(15 ⫾ 3)

79 ⫾ 3
(9 ⫾ 1)
83 ⫾ 3
(27 ⫾ 6)
77 ⫾ 2
(5 ⫾ 1)
83 ⫾ 1
(3 ⫾ 1)
15 ⫾ 4
(4 ⫾ 1)
225 ⫾ 5
(8 ⫾ 4)

4⫾2
(2 ⫾ 2)
2⫾1
(1 ⫾ 0)
2⫾1
(2 ⫾ 2)
15 ⫾ 2
(6 ⫾ 4)

4⫾2
(5 ⫾ 1)
18 ⫾ 1
(2 ⫾ 1)
6⫾2
(2 ⫾ 1)
5⫾2
(3 ⫾ 1)

*SFCs per 105 cells after overnight incubation with vv-infected autologous mature DCs (mean values of triplicates are shown).
‡Values in parentheses reflect reactivity using vvTK ⫺-infected DCs as control targets in the ELISPOT assay.
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1
2
3
4
5
6
7
8
9
10

vvTK⫺
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Results
CD4⫹ T Cells Consistently Recognize EBNA1. To evaluate adult CD4⫹ T cell responsiveness to EBV latency
gene products, CD8⫺CD2⫹ PBMC were stimulated for
2 wk with autologous DCs, separately infected with recombinant vv constructs expressing the EBV latent antigens
EBNA1, EBNA3A, EBNA3B, EBNA3C, LMP1, and
LMP2. For EBNA1, we also delivered the antigen as recombinant protein (rEBNA1) (42, 45). Responses were assessed by the presence of enlarged CD4⫹ T cells (“blasts”)
after 2-wk-long stimulations with DCs. In the first week,
one of a panel of vvEBV recombinants was used to stimulate the CD4⫹ T cells. Then the cultures were divided in
two and restimulated for a second week with the original
recombinant vv or with vvTK⫺ as control. We looked for
blastogenesis specific to the EBV recombinant that stimulated the CD4⫹ cultures in the first week.
All 10 donors showed strong responses to vvEBNA1
(Tables I and II, and Fig. 1, A and B). The response to the

Figure 1. EBNA1 is recognized by CD4⫹ T cells from healthy EBV
carriers. Blast formation (large forward scatter [FSC], x-axis) by CD4⫹ T
cells (CD4-FITC, y-axis) was monitored by flow cytometry. Cultures of
CD2⫹CD8⫺ T cells were stimulated with autologous DCs infected with
vv constructs. (A) Culture stimulated with vvEBNA1⌬GA-infected DCs
and restimulated with vvTK⫺-infected DCs. (B) Blasting of a culture
stimulated with vvEBNA1⌬GA-infected DCs and restimulated with
vvEBNA1⌬GA-infected DCs. (C) Culture stimulated with vvEBNA3Ainfected DCs and restimulated with vvTK⫺-infected DCs. (D) T cells
were stimulated and restimulated with vvEBNA3A-infected DCs. (E)
Culture stimulated and restimulated with vvTK⫺-infected DCs to evaluate the background of vaccinia stimulation. (F) CD2⫹CD8⫺ T cells responding to influenza virus–infected DCs as positive control. All cultures
were prepared from the same donor (no. 5 in Tables I and II). Percentage of blasted subpopulations (arrows) are indicated. 1⬚, first stimulation;
2⬚, restimulation.
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the restimulation to a final concentration of 10 U/ml (Lymphocult). Microcultures were tested in split well 51Cr-release assays
against autologous DCs infected with vvEBNA1⌬GA or vvTK⫺,
autologous B-LCLs, or LCL721.221. As ⬍30% of the wells developed CTLs or IFN-␥–secreting cells, it is ⬎90% probable that
the responding wells represent clones (50). The BC cell line was
generated separating EBNA1-specific CD4⫹ T cells after stimulation with vvEBNA1⌬GA-infected DCs using the IFN-␥ secretion assay according to the manufacturer’s instructions (Miltenyi
Biotec).
FACS® Analysis of Stimulated CD4⫹ T Cell Populations and
PBMCs. Mature DCs were infected with recombinant vv at an
MOI of 2, or with influenza virus (PR8, Puerto Rico/8/34;
Spafas, Inc.) at an MOI of 0.5 for 1 h at 37⬚C in RPMI 1640 HS.
DCs were washed twice, and 3 ⫻ 103 were added to 105 CD8⫺
CD2⫹ PBMCs in 96-well plates for 7 d. The cultures were restimulated with irradiated (3,000 rads) 105 PBMCs and 3 ⫻ 103 DCs
per well and incubated for an additional 7 d. At day 14, cultures
were stained for 30 min on ice with 1 l Simultest CD4-FITC/
CD8-PE (Becton Dickinson) and analyzed on a FACScan™
(Becton Dickinson). CD56 antibody staining (BD PharMingen)
used PE–goat anti–mouse IgG antibody (Biosource International)
as secondary. PBMCs were typed for HLA-DR4 using HLADR4 antibody (Accurate) as primary and FITC–goat anti–mouse
IgG antibody (Biosource International) as secondary.
Enzyme-linked Immunospot Assay for IFN-␥–secreting Cells.
Enzyme-linked immunospot (ELISPOT) assays were performed
as described previously (51). MAHA S45 plates (Millipore) were
coated with anti–IFN-␥ antibody 1-D1K (Mabtech). Plates were
blocked with DMEM plus 5% HS. Afterwards, 105 responder T
cells and 3 ⫻ 103 stimulator DCs or 104 B-LCLs were added per
well and incubated for 1–2 d. Where indicated, DCs, Ramos, or
LCL-BC cells were cocultured with twofold excess of allogeneic
vv expressing EBNA1 (vvEBNA1⌬GA), nonstructural protein 1
(vvNS1), or influenza matrix protein (vvMP)-infected DCs or allogeneic B-LCLs before cocultivation with T cells in the
ELISPOT plates. For DCs, this cocultivation was performed during maturation. Then the plates were incubated with biotinylated
anti-IFN-␥ antibody 7-B6-1 (Mabtech). Afterwards, preassembled avidin-peroxidase complex Vectastain ABC kit (Vector
Laboratories) was added. Spots were developed by addition of
stable DAB (Research Genetics). Plates were washed three times
with water and air dried. Spot-forming cells (SFCs)/105 cells
were counted using a stereomicroscope (mean counts of triplicates). Where indicated, anti–HLA-DR antibody L243 (52) or
anti–HLA-A, -B, -C antibody B-H9 (Biosource International)
was added to 5 g/ml.
Proliferation Assays. 105 responder T cells were incubated
with 3 ⫻ 103 to 104 stimulator DCs for 5 d in DMEM plus 5%
HS. 1 Ci [3H]thymidine was added/well overnight, harvested
by an automatic device (Skatron), and counted in a Betaplate
1205 (LKB Wallac). Counts represent mean values of triplicates.
51Cr-Release Assay.
Targets were labeled with 50 Ci
Na251CrO4 for 45 min at 37⬚C. Labeled targets were incubated for
4 h with CTLs in RPMI/10% FCS/2 mM glutamine. The supernatant was harvested using a Skatron harvesting system, and radioactivity was measured in a ␥ counter (1470 Wizard; LKB Wallac).
Percent specific lysis was calculated as ([cpm experimental well ⫺
cpm spontaneous release]/[cpm maximum release ⫺ cpm spontaneous release]) ⫻100%. Spontaneous release was determined
by incubating the labeled targets with medium, and maximum
release was determined by incubating targets in 1% Triton X-100
solution.

not shown). To establish that MHC class II products were
presenting EBNA1, we generated T cell lines, initially,
from an HLA-DR4⫹ donor. We then assessed reactivity of
the lines with DCs infected with recombinant vv expressing EBNA1 or pulsed with soluble EBNA1 protein. One
line, CM171198, was derived from CD8⫺CD2⫹ PBMCs
stimulated alternatively with autologous DCs infected with
vvEBNA1⌬GA or the DR4-matched B-LCL LRM. The
vvEBNA1 construct was deleted of the GA repeat that
blocks MHC class I presentation and also reduces expression of EBNA1. Another line, CM110199, was stimulated with DCs charged during their final maturation
with recombinant EBNA1 protein expressed either in
E. coli (eEBNA1) or in a baculovirus/insect cell system
(bEBNA1). After 1 mo of culture, both lines were predominantly CD4⫹ T cells, 90% in CM171198 and 76% in
CM110199, with CD56⫹ NK cells being the main contaminant (not shown).
The CD4⫹ T cell lines recognized DCs that were infected with vvEBNA1⌬GA or exposed to recombinant
EBNA1 (Fig. 3, A and B). Reactivity could be measured as
IFN-␥ secretion (ELISPOT assays, Fig. 3 A) or by proliferation (Fig. 3 B). The T cell responses were blocked by an
anti–HLA-DR antibody, L243, but not anti–HLA class I
antibody, B-H9 (Fig. 3 A). In addition to DCs charged
with EBNA1, the CM171198 cell line recognized EBVtransformed B-LCLs without further addition of antigen
(Fig. 3, A and B, bottom). In B-LCLs, only full-length
EBNA1 is expressed at detectable levels (24). This implies
that full-length EBNA1, as expressed endogenously by
B-LCLs, can be processed on MHC class II molecules for

Figure 2. Adult EBV-specific CD4⫹ T cells are
primed in vivo. CD4⫹ T cells from cord blood (C)
and adult leukocyte concentrates (B) were stimulated with autologous DCs infected with various recombinant vv or influenza virus as a control for 14 d.
The reactivities of the cultures were tested in IFN-␥
ELISPOT assays using autologous DCs infected
with the same recombinant vv as targets (TK⫺,
vvTK⫺; E1, vvEBNA1⌬GA; E2, vvEBNA2; E3B,
vvEBNA3B; E3C, vvEBNA3C; L1, vvLMP1; L2,
vvLMP2A; and B1, vvBMLF1). In a primary immune reaction, exemplified by alloreactivity (shown
for cord blood sample, #2 in A), adult and fetal
DCs and T cells functioned comparably.
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negative control (vvTK⫺) were weak (Fig. 1 E) in all but
one donor, excluded from the Tables. All donors responded to influenza-infected DCs as a positive control
(Fig. 1 F). CD4 T cell responses by the 10 donors to the
other vvEBV constructs were detected less consistently:
EBNA3B (5/10), EBNA3A (1/10), EBNA3C (1/10), and
LMP1 (6/10) (Table I). To ensure that all the recombinant
vv infected a comparable proportion of the mature DCs,
the intracellular expression of the 29-kD vaccinia early
protein was measured by FACS®. Reproducibly, 40–60%
of DCs were infected with the different vv (data not
shown). The reliability of the CD4⫹ recognition of
EBNA1 was also evident in an ELISPOT assay for IFN-␥
secretion, where EBNA1 was the EBV latency gene most
frequently recognized (Table II).
We regard these CD4⫹ T cell responses to EBNA1 to
reflect priming by EBV infection of the blood donors in
vivo, as we did not see blastogenesis in 2 wk if we stimulated neonatal T cells from cord blood specimens with
EBNA1 (Fig. 2). The fetal CD4⫹ T cells performed similarly to adult CD4⫹ T cells in MLR proliferation assays,
and the fetal DCs were likewise capable of eliciting strong
MLR proliferation of adult CD4⫹ T cells (Fig. 2 A).
However, none of the fetal samples were able to recognize EBV or influenza products in IFN-␥ ELISPOT assays
(Fig. 2). CD4⫹ T cells from adult controls recognized
vvEBNA1⌬GA, vvEBNA3B, vvLMP1, and influenzainfected autologous DCs in the same assay (Fig. 2).
CD4⫹ T Cells Recognize EBNA1 in an MHC Class II–
restricted Fashion. We verified that our donors showed HLA
class II diversity, as only two expressed HLA-DR4 (data

CD4⫹ T cell recognition. The B-LCLs had to be matched
at the DR4 allele to trigger T cell function. Thus, DR4⫹
B-LCLs (LRM and LCL-BM) induced proliferation, but
DR4⫺ cells (LG2 and LCL-DC) did not (Fig. 3, A and B,
bottom).
EBNA1-specific CD4⫹ T Cells Kill B-LCLs. To determine if EBNA1 was an antigen for CD4⫹ CTLs, we stimulated CD8⫺CD2⫹ PBMCs from an HLA-DR4⫺ donor,
JT, with irradiated autologous B-LCLs (expressing all
known latent EBV antigens [3]) for 2 wk. In parallel,
the B-LCLs were used to stimulate bulk CD2⫹ and CD4⫺
CD2⫹ T cells. The content of the stimulated T cell populations was determined by FACS®. CD8-depleted responders
were enriched for CD4⫹ cells, CD4-depleted responders
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Figure 3. Recognition of EBNA1 by a T cell line from an HLA-DR4⫹
donor stimulated with DCs loaded with soluble EBNA1 protein or a vaccinia-EBNA1 construct. (A) Top, IFN-␥ SFCs/105 cells upon stimulation
with DCs loaded with recombinant bEBNA1 protein (DC ⫹ bEBNA1)
or without loading (DC). Bottom, Spot formation upon incubation with
vvTK⫺-infected DCs (DC ⫹ vvTK⫺) or vvEBNA1⌬GA-infected DCs
(DC ⫹ vvEBNA1⌬GA). The MHC restriction is analyzed using the antibodies L243, anti–HLA-DR (⫹L243), and B-H9, anti–HLA class I (⫹BH9), for blocking. In addition, spot formation upon stimulation with the
HLA-DR4⫹ B-LCL LRM (LRM) versus the HLA-DR4⫺ B-LCL LG2
(LG2) is shown. (B) Proliferative responses of the CM171198 cell line
to various EBNA1 expressing targets. Top, APCs were DCs loaded
with rEBNA1 expressed in E. coli (eEBNA1), or baculovirus/insect
cells (bEBNA1), or DCs with a vv construct expressing EBNA1
(vvEBNA1⌬GA) or vector alone (vvTK⫺). Bottom, the APCs were
B-LCLs sharing the HLA-DR4 allele (LRM and LCL-BM) with the
CM171198 cell line, or mismatched for HLA-DR4 (LG2 and LCL-DC).

were enriched for CD8⫹ cells, and the bulk T cells had a
CD4⫹/CD8⫹ ratio of 1:2 (see Fig. 5, top). All contained
ⵑ25% CD56⫹ NK cells (not shown).
51Cr-release assays showed that the three populations of
stimulated T cells killed autologous B-LCLs, with less recognition of the T2 cell line (Fig. 4, bottom left). As expected, the killing of autologous B-LCLs was completely
blocked by L243 anti–HLA-DR antibody when CD4⫹enriched populations, but not CD8⫹-enriched cultures,
were tested (Fig. 4, bottom left). However, the CD8enriched cultures repeatedly developed stronger cytolytic
activity than CD4-enriched cultures. Killing by the bulk T
cells was partially inhibited by the L243 antibody, but the
block was ⱕ50% in our three experiments.
EBNA1-specific CTL function was also assessed using
DC targets that had been infected with vvEBNA1⌬GA or
recombinant eEBNA1 and bEBNA1 proteins (Fig. 4).
CD4⫹-enriched T cells lysed EBNA1-pulsed DCs. In contrast, CD8⫹-enriched cultures and bulk T cells were able
to kill LCLs, but not the EBNA1-pulsed DCs (Fig. 4, bottom right).
To begin to determine if individual CD4⫹ T cells could
lyse DCs pulsed with EBNA1, as well as B-LCLs expressing EBNA1 endogenously, we used autologous B-LCLs to
isolate CD4⫹ CTLs by limiting dilution from cryopreserved T cells. The DCs, T cells, and autologous B-LCLs
were derived from leukocyte concentrates. All 11 limiting
dilution sublines that killed DCs in an EBNA1-dependent
fashion also killed autologous B-LCLs, and we did not find
any clone that killed the DCs and not the B-LCLs (Fig. 5).
This indicates a tight correlation between recognition of
epitopes expressed by B-LCLs and recognition of DCs that
have been pulsed with EBNA1. As we were studying cells
obtained under limiting dilution conditions, with ⬍30%
recognizing B-LCLs, it is ⬎90% likely that individual
clones were responsible for killing DCs and B-LCLs, although formal cloning experiments will be required (50).
Recognition of DCs infected with the vvTK⫺ control vector or LCL721.221, an HLA class I–negative NK target,
was poor in all 11 sublines (Fig. 5). Therefore, CD4⫹ T
cells can lyse autologous B-LCLs, and one target very likely
is EBNA1.
EBNA1 Is Recognized on B-LCLs after Endogenous Processing. As we were observing EBNA1-specific CD4⫹ cells
that make Th1 cytokines and exert cytolytic activity upon
encountering transformed B-LCLs, it was important to establish that this new and potentially protective mechanism
would operate on EBNA1 that was processed endogenously by transformed B cells. The alternative would be
that in our cultures some cells were dying and were being
reprocessed via an exogenous or endocytic pathway in a
fraction of LCLs. We are not aware of inhibitors that efficiently and selectively block processing of EBNA1 from an
endogenous or exogenous route.
Therefore, we first compared the capacity of DCs (as a
positive control) and the EBV⫺ Burkitt’s lymphoma cell
line, Ramos, to present EBNA1 through an exogenous
pathway, either rEBNA1 protein or EBNA1 expressed by

allogeneic B-LCLs (Fig. 6 A). Because of MHC class II
mismatching, the allogeneic B-LCLs could not directly
present EBNA1 to T cell lines that had been selected for
IFN-␥ secretion upon stimulation with vvEBNA1⌬GAinfected autologous DCs. The Ramos cell line as well as
the autologous DCs could present vvEBNA1⌬GA to an
EBNA1-specific CD4⫹ T cell line from a donor matched
at HLA-DR7 to Ramos (Fig. 6 A). In contrast, only the
DCs, and not the Ramos Burkitt’s lymphoma cells, presented exogenous rEBNA1 and EBNA1 from allogeneic
LCLs (having ⵑ20% trypan blue–positive or dead cells;
Fig. 6 A).
DCs also presented EBNA1 from additional exogenous
sources. In Fig. 6 B, DCs presented EBNA1 from four
different allogeneic DC preparations infected with
vvEBNA1⌬GA, presumably because infection with vv is
cytotoxic for some of the infected DCs (49). As vv-infected
DCs cannot produce virus particles (49, 53), coinfection
could not be responsible for the observed EBNA1 transfer
from one DC to another. A fifth semiallogeneic DC preparation presented vvEBNA1⌬GA directly to the T cell line
(Fig. 6 B).
Although there is already evidence in the literature that
Burkitt’s lymphoma cells are comparably efficient to
B-LCLs in presenting soluble antigen on MHC class II (54),
we wanted to show that both types of lymphoma also share
the inability to cross-present antigen from cocultured cells.
Therefore, we infected mismatched DCs and EBV latency
III type Daudi cells with recombinant vv expressing influenza NS1 or MP, and then looked for cross-presentation of
these influenza products by autologous B-LCLs or DCs, to
CD4⫹ T cells of an influenza-reactive donor. Again, the
DCs could present antigen from the allogeneic vvNS1- or
vvMP-infected cells, but the B-LCLs could not (Fig. 7). As
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a positive control, we showed that autologous B-LCLs
could present NS1 (Fig. 7 A) and MP (Fig. 7 B) to CD4⫹
T cells when directly infected with vvNS1 or vvMP, respectively. Coculturing B-LCLs with allogeneic infected
B-LCLs for 2 d apparently did not transfer sufficient antigen amounts to the matched B-LCLs to trigger IFN-␥ secretion by CD4⫹ T cells. In contrast NS1- or MP-expressing allogeneic B-LCLs could be efficiently processed by
DCs and presented to CD4⫹ T cells.
This series of experiments indicates that DCs efficiently
cross-present on MHC class II antigens (EBNA1, NS1, and
MP) from allogeneic DCs or B-LCLs, but that transformed
B cells (B-LCLs or Burkitt’s lymphoma cells) are weak or
inactive in this respect. The findings are consistent with
prior publications showing that B-LCLs can present soluble
proteins that bind to their Ig receptor, but not by a nonspecific exogenous route (55). Therefore, CD4 T cell recognition of EBNA1 in B-LCLs very likely represents recognition of the endogenously processed protein that is critical
for EBV-induced transformation.

Discussion
EBNA1-specific CD4⫹ T Cell Immunity Exists in All
Healthy Adults. In an effort to define the CD4⫹ T cell
repertoire for EBV latency gene products, we have uncovered a consistent CD4⫹ T cell response to EBNA1 presented by DCs and by autologous B-LCLs. The EBNA1specific CD4⫹ T cells proliferate, secrete IFN-␥, kill
targets, and can be readily propagated as EBNA1-specific,
MHC class II-restricted lines. Other latency antigens
(LMP1, LMP2, EBNA3A, EBNA3B, and EBNA3C; Tables I and II) can be recognized by CD4⫹ T cells, but less
consistently. The CD4⫹ T cells described here are found in
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Figure 4. HLA-DR restriction and EBNA1 recognition by
T cell subsets. Different populations of PBMCs (CD2⫹,
CD8⫺CD2⫹, or CD4⫺CD2⫹)
were stimulated for 2 wk with
autologous B-LCL. Top, the effectors were analyzed by FACS®
for CD4 and CD8 expression.
Bottom left, cytolysis of autologous B-LCL (LCL-JT) in the
presence or absence of 5 g/ml
L243, anti–HLA-DR antibody
(LCL-JT ⫹ L243). T2 cells are
targets for NK cells. Bottom
right, lytic activity against autologous B-LCL (LCL-JT) compared with autologous DCs
pulsed with E. coli–derived control protein (eControl), E. coli–
derived EBNA1 (eEBNA1), or
baculovirus/insect cell–derived
EBNA1 (bEBNA1). % spec. lysis, percent specific lysis.

Figure 6. DCs are efficient, and B-LCLs inefficient, in presenting
EBNA1 by an exogenous pathway. (A) The EBNA1-specific HLADRB*0701⫹CD4⫹ T cell line BC, selected for IFN-␥ secretion upon
stimulation with vvEBNA1⌬GA-infected autologous DCs, responds
comparably to vvEBNA1⌬GA-infected autologous DCs and
vvEBNA1⌬GA-infected HLA-DRB*0701⫹ Ramos cells. DCs, but not
Ramos cells, present recombinant EBNA1 proteins and allogenic LCLJT. (B) The EBNA1-specific CD4⫹ T cell line 090199.6 recognized autologous DCs either infected with vvEBNA1DGA, or cocultured with
infected allogeneic (allo) DCs. Semiallogeneic (semiallo) DCs were recognized irrespective of coculturing with autologous DCs.

bulk cultures and kill B-LCLs without further addition of
EBNA1. The results are in marked contrast to the prior literature that has described only a single EBNA1-specific
CD4⫹ T cell clone, and it only killed B-LCL targets upon
supplementation with exogenous EBNA1 (39). The consistent detection of EBNA1 immunity in our studies could
reflect the use of CD4⫹ T cells as responders, and DCs as
APCs.
The consistent recognition of EBNA1 by CD4⫹ T cells
is strikingly different from CD8⫹ T cells. CD8⫹ T cells,

specific for EBNA1-derived MHC class I epitopes, can be
found in blood, but they do not recognize autologous or
HLA-matched B-LCLs (24). This indicates that the physiological levels of EBNA1 are not sufficiently processed onto
MHC class I, nor do B-LCLs cross-present EBNA1 when
B-LCLs die in culture. The block of endogenous processing of EBNA1 is well understood, i.e., the Gly/Ala repeat
prevents efficient proteasomal degradation and therefore
epitope generation for MHC class I presentation (25, 26).
In light of the efficient cross-presentation of antigens on
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Figure 5. EBNA1-specific CD4⫹ CTL sublines kill B-LCLs. B-LCLs
were generated from two leukocyte concentrates. Cryopreserved
CD8⫺CD2⫹ PBMCs were then stimulated for 2 wk with the autologous
B-LCLs under limiting dilution. Then the wells were split and tested in
51Cr-release assays against vvEBNA1⌬GA- or vvTK⫺-infected DCs as
well as autologous B-LCLs and LCL721.221, an HLA class I⫺ NK target.
The dot plot shows for the first experiment, as an example, the CTL
specificities that could be detected above three times the SD (3⫻SD) of
the unspecific targets. Only CTLs exclusively recognizing autologous
B-LCLs or recognizing autologous B-LCLs and vvEBNA1⌬GA-infected
autologous DCs could be detected. All 11 sublines that recognized
EBNA1-expressing DCs also demonstrated specific killing of autologous
EBV-transformed B cells.

MHC class I by DCs (56), it is likely that the observed
EBNA1-specific CD8⫹ T cells are primed by DCs that
process B-LCLs onto MHC class I. However, because of
the Gly/Ala repeat, such CD8⫹ T cells would not see
EBNA1 expressed by EBV-infected cells.
Evidence That Endogenous Processing and Presentation of
Physiological Epitope Levels on B-LCLs Are Sufficient to Elicit
EBNA1-specific CD4⫹ T Cell Immunity. The EBNA1specific CD4⫹ T cells described in this study recognize autologous B-LCLs by proliferation, IFN-␥ secretion, and
cytolysis. As these responses are MHC class II restricted,
and because EBNA1 is expressed endogenously in B-LCLs,
two routes of processing can be envisioned. Either EBNA1
is processed directly by the EBV-infected cell itself (endog1657
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Figure 7. Influenza antigens are efficiently cross-presented by DCs, but
not B-LCLs. Allogeneic DCs (alloDC2) and the latency III type Burkitt’s
lymphoma cell line Daudi were infected with recombinant vv expressing
either (A) NS1 (vvNS1), or (B) influenza MP (vvMP). Then DCs and BLCLs were cultured with maturing DCs or B-LCLs derived from another
healthy adult donor for 2 d at a ratio of vv-infected cells to presenting
cells of 2:1 (DC⫹/B-LCL⫹). CD2⫹CD8⫺ PBMCs autologous to the
presenting cells were tested in IFN-␥ ELISPOT assays. As controls, the
presenting DCs or B-LCLs were also directly infected with vvNS1 and
vvMP or vvTK⫺ as control (DCvvTK⫺/DCvvNS1/DCvvMP or B-LCLvvTK⫺/
B-LCLvvMP/B-LCLvvNS1).

enous pathway), or dying EBNA1-expressing B-LCLs are
endocytosed and presented (indirect or exogenous or crosspresentation pathway). This does not necessarily mean that
the processing machinery differs, but that in the first endogenous case the antigen is processed in the cell that synthesizes EBNA1, making it a more reliable target for protective immunity in humans. From our experiments,
exogenous processing is an unlikely explanation for presentation of EBNA1 on B-LCLs, as antigen transfer from
HLA-mismatched cells was not observed (Fig. 6). B-LCLs
were previously shown to be poor APCs for exogenous
proteins (55), 100–300 times less efficient than DCs. Similarly we found that the Ramos Burkitt’s lymphoma line inefficiently processed rEBNA1 and cross-presented EBNA1
from cocultured B-LCLs to CD4⫹ effector cells (Fig. 6 A).
Cross-presentation of influenza NS1 and MP by B-LCLs
from vvNS1- or vvMP-infected DCs or EBV latency III
type Daudi cells was also inefficient (Fig. 7). In contrast, DCs
cross-presented antigen from B-LCLs or vvEBNA1⌬GAinfected DCs, and processed rEBNA1 (Fig. 6, A and B).
This was not restricted to EBNA1, as DCs also presented
NS1 and MP from cocultured vvNS1- and vvMP-infected
DCs and Daudi cells (Fig. 7). As a positive control for the
competence of the lymphoma cells as APCs, we showed
that direct infection of Ramos or B-LCL cells with recombinant EBNA1 or influenza vv led to CD4⫹ T cell responses. This implies that in healthy carriers, the DCs that
are known initiators of immune responses (41) crosspresent B-LCL–derived EBNA1 for priming of specific
CD4⫹ T cells. Once activated, these CD4⫹ T cells may attack B cells that process EBNA1 endogenously and contribute to EBV-specific immunity.
The Gly/Ala Repeat Domain Does Not Influence MHC
Class II Processing of EBNA1. Our experiments confirm
that EBNA1 can be processed onto MHC class II irrespective of the presence or absence of its Gly/Ala repeat. This
domain inhibits proteasome-dependent processing for
MHC class I (25, 26). B-LCLs, the only reliable source of
full-length EBNA1 (24), readily present EBNA1 to specific
CD4⫹ T cells (Figs. 2–4). Moreover, B-LCLs with fulllength EBNA1 can be cross-presented by DCs (Fig. 5 B).
Therefore, the proposal that EBNA1 prevents its endogeous MHC class II presentation (39) cannot be supported by our findings.
Evidence That CD4⫹ T Cell Immunity Could Contribute to
the Control of EBV. EBNA1-specific CD4⫹ T cells could
provide direct resistance to EBV-transformed cells, through
their cytokines and lytic function or by sustaining the
CD8⫹ CTL response to other lymphoma-related EBV
products such as LMP1 and LMP2. A good deal of circumstantial evidence for CD4⫹ T cell protection against
gamma herpesviruses in vivo exists. (a) CTLs to EBV in the
cottontop tamarin Sanguinis oedipus (57) are to a large extent MHC class II restricted (58). MHC class I–restricted,
EBV-specific CTLs have yet to be found in this New
World monkey, and this species lacks classical MHC class I
(although it does express homologues of nonclassical class I
genes like HLA-G and HLA-F; 59). (b) Gamma herpesvi-
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rus infection in mice by MHV-68 can be controlled by
IFN-␥–secreting CD4⫹ T cells (60). (c) Control of the
growth of EBV-transformed B cells by CD4⫹ T cells has
been described in culture (61). (d) Early in HIV-1 infection, when CD4⫹ T cell counts are still high but CD4⫹ T
cell function starts to be compromised, patients can develop Burkitt’s lymphomas, expressing only the EBNA1
EBV latency gene product, rather than mononucleosis with
all nine EBV latency gene products (62). (e) Impaired
CD4⫹ responses are thought to be responsible for the
EBV-induced infectious mononucleosis seen in X-linked
lymphoproliferative disease patients who have a mutation
or deletion in signalling lymphocyte activation molecule
(SLAM)-associated protein (SAP), an inhibitor of the T cell
costimulatory molecule SLAM or CDw150 (63). This lack
in SLAM function especially affects Th1 immunity, as
SLAM engagement mediates increased IFN-␥ secretion
(64, 65). Thus, EBNA1-specific Th1 cells are probably disabled in X-linked lymphoproliferative patients.
Our findings uncover an immune response that changes
current thinking on immune surveillance against EBV. The
data on CD4⫹ T cell responses to EBV latent antigens in
bulk T cell preparations place EBNA1 at the top of the recognition hierarchy. Previously, the specificities of only two
isolated CD4⫹ T cell clones have been described (39, 54).
Since only the EBNA2-specific CD4⫹ T cell clone recognized B-LCLs, the significance for CD4⫹ T cell recognition was questionable, particularly in the context of latency
I and II programs of EBV transformation. However, the
new data reveal a hierarchy of CD4⫹ T cell recognition
that differs significantly from CD8⫹ T cell responses to
EBV (28). EBNA3A, EBNA3B, and EBNA3C antigens
dominate for CD8⫹ T cell recognition, but play a subdominant role for CD4⫹ T cells. In contrast, EBNA1, believed
to be invisible to the immune system because of a block in
its MHC class I presentation (24), is the main target of
MHC class II–restricted CD4⫹ T cell responses. As we find
these responses in all tested healthy adults, we suggest that
EBNA1-specific CD4⫹ T cells provide resistance to the
development of Burkitt’s lymphomas, Hodgkin’s, and
other EBV-associated malignancies. Likewise, the new data
suggest that EBNA1 be tested as an antigen to prevent and
treat such malignancies.
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